The psychiatric treatment landscape stands at an inflection point as psychedelic compounds transition from decades of regulatory exile to potential clinical mainstream adoption. This shift reflects both the urgent need for effective interventions in treatment-resistant mental health conditions and mounting evidence that compounds like psilocybin, MDMA, and ketamine can produce rapid, sustained improvements in mood and behavior where conventional therapies fail. The analysis of phase II-III trial data across ketamine/esketamine, MDMA, psilocybin, LSD, DMT variants, and ibogaine demonstrates therapeutic promise for major depression, treatment-resistant depression, PTSD, anxiety disorders, and substance use disorders. However, these compounds demand fundamentally different delivery models than traditional psychiatric medications. Rather than simple prescription protocols, psychedelic-assisted therapies require specialist-delivered, psychotherapy-integrated care under stringent regulatory oversight. This integration necessity stems from the compounds' profound psychological effects and the therapeutic importance of set, setting, and guided processing of the psychedelic experience. The regulatory complexity spans multiple jurisdictions with varying scheduling constraints and approval pathways, creating a patchwork of access mechanisms. Critical unresolved challenges include establishing long-term safety profiles, developing scalable workforce training programs, ensuring equitable access across socioeconomic strata, and defining clear medico-legal accountability frameworks. While late-stage trials support efficacy in high-need populations, the transition from research to clinical practice requires addressing these systemic implementation barriers before psychedelic medicine can fulfill its therapeutic potential.